Rivian Automotive, Inc. vs Zoetis Inc — how do they compare? Rivian Automotive, Inc. trades at $13.93 (market cap $20.75B), while Zoetis Inc trades at $74.4 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Zoetis Inc for 70 Days on average.
| RIVN | ZTS | |
|---|---|---|
Market Cap | $20.75B | $30.20B |
Volume | 26,144,654 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $147.53 |
52-Week Low | $12.50 | $69.09 |
Typical Hold Time | 61 Days | 70 Days |
Enterprise Value | $20.79B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.03, down 2.16% amid bearish technical signals despite beating Q3 2026 delivery estimates with 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving revenue trends and cash flow reduction. Analyst consensus remains cautiously optimistic with a $16.89 price target, though technical indicators show selling pressure with RSI near oversold levels.
Rivian presents a high-risk growth opportunity with significant operational improvements but persistent losses. The R2 SUV rollout and autonomy technology development offer long-term potential, while near-term challenges include cash burn and competitive EV market pressures. Investors should weigh improving fundamentals against substantial execution risks in a capital-intensive industry.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
Latest headlines on both assets
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →